Ten years after the original Dieselgate scandal erupted with Volkswagen, the UK finds itself back in the spotlight. In 2025, a landmark legal battle unfolds in London as millions of diesel car owners bring lawsuits against major automakers.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
The telecom industry has long been an anchor for communication, connectivity, and digital progress. Yet beneath the surface, a troubling issue is emerging. Vodafone franchisees across the United Kingdom are voicing deep concerns about their mental health following a wave of commission cuts. Reduced earnings are not only affecting their financial stability but also taking…
Five years can feel like a short time in our lives, but in the stock market, it can change everything. Back in 2019, many UK investors were looking at Vodafone shares as a safe choice. It was one of the largest telecom companies in Europe, known for its strong customer base and steady dividend payouts….
Anglo American announced its merger with Canadian rival Teck Resources on September 9, 2025. This deal creates a $53 billion mining giant focused on critical minerals. The merger forms one of the world’s largest copper producers. Continue Reading on Meyka This article is available in full on our main platform. Get access to complete analysis,…
On August 13, Bullish Stock Soars in a dazzling debut on the NYSE, delivering a whopping 90 per cent gain by closing at $70, and pushing its valuation to roughly $10 billion. This debut marks one of the standout crypto exchange IPO surges, reflecting renewed investor appetite for digital asset platforms. Continue Reading on Meyka…
Disney Stock drew fresh investor attention after a regulatory filing showed the Czech National Bank added 24,176 shares to its position in The Walt Disney Company. The move was posted in the latest Form 13F disclosure, and it reached trading desks and market feeds within hours. Continue Reading on Meyka This article is available in…
GlaxoSmithKline, widely known as GSK, recently reported a robust first half of 2025, with strong performance in its specialty medicines division and a bold forecast upgrade. Yet, paradoxically, the GSK share price remains weak, down around 16% from its year-high, despite evidence pointing to deep undervaluation. Continue Reading on Meyka This article is available in…